Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

29

Jul 2026

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

ALS risk varies significantly across U.S. military service branches

29

Jul 2026

ALS risk varies significantly across U.S. military service branches

Compared to Army veterans, men who are veterans of the U.S. Air Force, Navy and Coast Guard have higher rates of amyotrophic lateral sclerosis (ALS), and men who are Marine veterans have lower rates, according to a new study published July 29, 2026, in Neurology®, an official journal of the American Academy of Neurology.

Low-fat diet lowers dietary glycation compounds for years in postmenopausal women

29

Jul 2026

Low-fat diet lowers dietary glycation compounds for years in postmenopausal women

Researchers analyzing dietary data from 40,209 postmenopausal women found that a low-fat pattern emphasizing fruits, vegetables, and grains was associated with sustained reductions in estimated dietary advanced glycation end-product intake over approximately seven years. The findings suggest broad dietary changes may lower dAGE intake without specific cooking instructions, although the study did not measure biological AGE exposure or determine whether the reductions influenced breast cancer outcomes.

Early-life sugar restriction may reduce dementia risk later

29

Jul 2026

Early-life sugar restriction may reduce dementia risk later

Consuming less sugar in utero before birth and during the first one to two years of life was associated with a lower risk of developing dementia later in life, according to a study published July 29, 2026, in Neurology, the medical journal of the American Academy of Neurology.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.